Market Intelligence, Clinical Progress, and High-Purity Reagents for BAP1-Driven Cancer Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BAP1 Recombinant Protein (Full-Length & Catalytic Domain). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Wild-type, catalytic-dead (C91A, C91S), cancer-associated truncation mutants (including KURIS variants rs2153228682, rs2153228535) and loss-of-function variants available. | View BAP1 Products |
| Gene Delivery | BAP1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line reconstitution and rescue assays in BAP1-null backgrounds. | View BAP1 Products |
| Benchmark Ab | Anti-BAP1 Recombinant Antibody. Biosimilar positive control validated for IHC, Western blot, IP. | View BAP1 Products |
| Validator | BAP1 siRNA Set. For knockdown verification and synthetic lethality screening. | View BAP1 Products |
| Related Target A | EZH2. Synthetic lethality partner; clinically validated target in BAP1-loss cancers. | View EZH2 Products |
| Related Target B | ASXL1. Scaffolding partner in the PR-DUB complex; essential for BAP1 chromatin recruitment and complex reconstitution. | View ASXL1 Products |
| Related Target C | PARP1. DNA damage response overlap; synthetic lethality target in BAP1-deficient contexts. | View PARP1 Products |
| Related Target D | UCHL1. Related DUB family member for selectivity counter-screening. | View UCHL1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Loss-of-function mutant validation | Cancer-associated BAP1 mutants (C91A catalytic dead, C-terminal truncations, KURIS variants) with Sequence Verified purity >95% |
| DUB enzymatic activity & compound screening | Catalytically active WT protein, validated Ub-AMC hydrolysis; C91A/S catalytic dead mutant as negative control; Endotoxin <1 EU/µg |
| PR-DUB complex reconstitution | Full-length BAP1 + ASXL1 proteins for binding affinity determination (SPR/ITC) |
| Synthetic lethality validation & rescue assays | Matched WT and cancer-variant BAP1 lentivirus for isogenic line construction; BAP1 Lentivirus & ORF for stable reconstitution in null mesothelioma and uveal melanoma lines |
| Off-target / counter-screening | Homolog panel (UCH-L1, UCH-L3, USP1, USP7) with >95% purity for DUB selectivity profiling |
| Biomarker specificity (IHC/IF) | Benchmark Anti-BAP1 antibodies with defined epitope mapping for BAP1-loss detection |
| Cellular localization studies | Native conformation preserved in HEK293-expressed proteins; validated for immunofluorescence standards |
| Lack of reliable controls | Clinical benchmark antibodies and matched mutant proteins included as positive/negative controls |
Live BAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for BAP1 is distinct from classic oncogene targeting. Because BAP1 functions as a tumor suppressor deubiquitinase, the dominant clinical paradigm is synthetic lethality in BAP1-deficient malignancies. Loss-of-function mutations drive 60-80% of malignant mesotheliomas and uveal melanomas. First-generation EZH2 inhibitors (e.g., tazemetostat) have shown signals in BAP1-loss mesothelioma, while PARP inhibitor combinations and EZH2i + immunotherapy are advancing. The field is pivoting toward direct modulation of BAP1 catalytic activity, disruption of the BAP1-ASXL1 (PR-DUB) interface, and next-generation modalities such as DUBTACs (deubiquitinase-targeting chimeras) and PROTACs. Emerging R&D also targets chromatin remodeling complexes and metabolic vulnerabilities to bypass acquired resistance. Biochemical tool development prioritizes selective DUB inhibitors for immune regulatory contexts and complex reconstitution assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Synthetic Lethality (EZH2i / PARPi) | Ipsen (Epizyme), AstraZeneca, NCI, Kura Oncology | Malignant Pleural Mesothelioma, Uveal Melanoma, RCC | Rescue Cell Lines (Need BAP1 Lentivirus for reconstitution) |
| DUB Modulators (Activators / Inhibitors) | Preclinical / Emerging Biotech, AbbVie, Alentis Therapeutics | Solid Tumors (BAP1-intact), Fibrosis, Immuno-oncology | Enzymatic Assay (Need high-purity WT & C91A/S mutant proteins) |
| PPI Disruptors (BAP1-ASXL) | Academic / Early Discovery | Leukemia, Solid Tumors | Co-binding Assay (Need BAP1 + ASXL1 heterodimer proteins) |
| Gene Therapy | Advirna, Various Academia | BAP1 Loss Syndromes | Protein Expression Validation (Need high-titer ORF Lentivirus) |
| PROTACs / DUBTACs | Novartis, Arvinas, Vicinitas Therapeutics | BAP1-Deleted Cancers, Solid Tumors | Ternary Complex Formation (Need full-length BAP1 and partner proteins; intact ubiquitin-binding domains) |
| Biomarker IHC Antibodies | Various Diagnostics Companies | Renal Cell Carcinoma, Mesothelioma | Epitope Specificity (Need sequence-verified recombinant fragments) |